Alkylation of a catalytic aspartate group of the SIV protease by an epoxide inhibitor.

Alkylation of a catalytic aspartate group of the SIV protease by an epoxide inhibitor.

Bioorg Med Chem. 1997 Nov;5(11):2019-27. Unique Identifier : AIDSLINE MED/98078375
Caldera PS; Yu Z; Knegtel RM; McPhee F; Burlingame AL; Craik CS; Kuntz ID; Ortiz de Montellano PR; Department of Pharmaceutical Chemistry, School of Pharmacy, University; of California, San Francisco 94143-0446, USA.

Abstract: Specific irreversible inhibition of the SIV protease by FMOC-protected piperidine epoxide 1 involves alkylation of the protein. Tryptic digestion of the alkylated protein and mass spectrometric analysis of the peptides identify an active site aspartic acid (Asp-25) as the single residue that is alkylated. Computer modeling of 1 bound in the crystal structure of the SIV protease using DOCK 3.5 indicates that 1 has appropriate access to the active site. It is able to align in an orientation that allows a proton to be transferred to the epoxide from one of the catalytic aspartic acid groups in conjunction with nucleophilic attack on the epoxide of the carboxylate moiety of the second catalytic aspartic acid residue. Hydrophobic interactions are not optimal for this process due, in part, to the rigidity of the inhibitor ring system and the planar conformation of the amide. The combination of modeling with protein alkylation can provide insights into structural modifications of the inhibitor that may lead to improved inhibitory activity.

Keywords: *Antiviral Agents/PHARMACOLOGY *Aspartic Acid/METABOLISM *Aspartic Proteinases/ANTAGONISTS & INHIB *Aspartic Proteinases/METABOLISM *Epoxy Compounds/PHARMACOLOGY *Protease Inhibitors/PHARMACOLOGY *SIV/ENZYMOLOGY
980430
M9841523

ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGiS, or the party credited as the provider of the content.